The commercialisation firm will cut cash operating expenses by more than 40% year-on-year, while SciFluor Life and Precision Biopsy received $9m in financing between them.
Commercialisation firm Allied Minds intends to pare back its operating costs by more than 40% year-on-year as it braces itself for what the firm described as “challenging capital markets” ahead. Allied Mind’s headquarters cash operating expenses are expected to be $5.6m less than in 2018. The firm’s chief executive, Jill Smith, has agreed to reduce…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
